The FDA's advisory committee will focus on checkpoint inhibitors from Bristol-Myers (BMY) and Merck (MRK).

On September 26, the US FDA's Oncologic Drugs Advisory Committee will focus on the use of two widely used checkpoint inhibitors, Opdivo (nivolumab) from Bristol-Myers Squibb (BMY.US) and Keytruda (pembrolizumab) from Merck (MRK.US), for the treatment of various cancers, with the goal of discussing the use of the drugs in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma and metastatic esophageal squamous cell carcinoma. Yervoy (ipilimumab) from Bristol-Myers Squibb will also be discussed as part of the esophageal cancer treatment discussion.